Precision oncology for lung cancer depends entirely on knowing a tumor's molecular fingerprint — yet large portions of patients never receive that information. A dataset of this scale offers a rare opportunity to quantify exactly where the gap between testing capability and clinical practice is widest, and which patient groups are being left behind.
Analyzing 82,328 non-small cell lung cancer (NSCLC) samples profiled by comprehensive genomic profiling via next-generation sequencing between 2014 and 2022, investigators found that 35.1% of cases harbored at least one actionable genomic alteration — a mutation for which an FDA-approved or emerging targeted therapy exists. The rate was highest in lung adenocarcinoma (45.8%) and adenosquamous carcinoma (40.9%), while squamous cell carcinoma, large cell carcinoma, and not-otherwise-specified subtypes showed substantially lower but non-trivial actionable mutation rates of 21% or below. This gradient underscores that even histologic subtypes traditionally considered less "targetable" carry meaningful frequencies of druggable alterations.
This analysis represents one of the largest single-assay genomic profiling datasets ever published for NSCLC, lending unusual statistical power to subgroup comparisons across histologic and clinicodemographic categories. The finding that more than one-fifth of squamous cell cases carry actionable alterations is clinically consequential: current practice often deprioritizes comprehensive testing in squamous histology, meaning a significant fraction of those patients may never be offered matched therapy. The retrospective, observational design limits causal inference, and the cohort likely skews toward academic or well-resourced centers using FoundationOne/CDx, potentially overstating real-world testing access. Still, this study builds a compelling evidence base for universal molecular testing regardless of histologic subtype — a recommendation that remains unevenly implemented globally. For health-conscious adults navigating a lung cancer diagnosis or supporting a family member, this research reinforces the importance of insisting on comprehensive biomarker evaluation at diagnosis.